Akari Therapeutics Plc Sponsored ADR ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Akari Therapeutics Plc Sponsored ADR zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Akari Therapeutics Plc Sponsored ADR zu Deinem Portfolio hinzuzufügen.
BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will present new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model at the upcoming As...
BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Akari Therapeutics, Plc (NASDAQ: AKTX) and Peak Bio Inc. is fair to Akari shareholders. Halper Sadeh encourages Akari shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or ...
BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc. (OTC: PKBO), a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to me...
BOSTON and LONDON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it closed a private placement financing with existing investors, Akari Chairman Dr. Ray Prudo and Director Samir R. Patel, M.D., on December 29, 2023, resulting in gross procee...
NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that President and CEO Rachelle Jacques will present a company overview for in-person and virtual attendees at Biotech Showcase taking place in San Francisco, CA January 8-10, 202...
NEW YORK and BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. to the Akari Board of Directors.
Positive pre-clinical results, including an advanced high yielding manufacturing process, support the anticipated submission of an IND in 2024 to begin clinical development with Phase 1 single and multiple ascending dose (SAD/MAD) testing to evaluate safety and pharmacokinetics/pharmacodynamics (PK/PD) of long-acting PAS-nomacopan Positive pre-clinical results, including an advanced high yieldi...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.